Alpine Immune Sciences Inc (NASDAQ:ALPN) has earned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.96.
A number of equities research analysts recently weighed in on ALPN shares. Zacks Investment Research raised shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Thursday, May 21st. Wedbush raised their price target on shares of Alpine Immune Sciences from $10.00 to $22.00 and gave the company an “outperform” rating in a report on Friday, June 19th. Piper Sandler raised their price objective on shares of Alpine Immune Sciences from $8.00 to $21.00 in a report on Friday, June 19th. ValuEngine raised shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $17.00 price objective on shares of Alpine Immune Sciences in a report on Tuesday, May 26th.
A hedge fund recently raised its stake in Alpine Immune Sciences stock. Renaissance Technologies LLC increased its holdings in Alpine Immune Sciences Inc (NASDAQ:ALPN) by 13.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 127,810 shares of the biotechnology company’s stock after buying an additional 15,449 shares during the period. Renaissance Technologies LLC owned about 0.69% of Alpine Immune Sciences worth $491,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 43.87% of the company’s stock.
Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.17. The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $0.38 million. Alpine Immune Sciences had a negative net margin of 1,236.45% and a negative return on equity of 104.04%. On average, research analysts predict that Alpine Immune Sciences will post -0.04 earnings per share for the current year.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Article: What is a good rate of return for a mutual fund?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.